FocalTherics (FOCL) Competitors

$3.17 -0.07 (-2.16%)
As of 04:00 PM Eastern

FOCL vs. ANGO, SI, NPCE, BWAY, and SENS

Should you buy FocalTherics stock or one of its competitors? FocalTherics's main competitors and comparable companies include AngioDynamics (ANGO), Shoulder Innovations (SI), NeuroPace (NPCE), Brainsway (BWAY), and Senseonics Holdings, Inc. Common Stock (SENS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does FocalTherics compare to AngioDynamics?

AngioDynamics (NASDAQ:ANGO) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

FocalTherics has lower revenue, but higher earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AngioDynamics$320.17M1.56-$36.74M-$0.78N/A
FocalTherics$70.53M1.72-$29.25M-$0.98N/A

In the previous week, FocalTherics had 10 more articles in the media than AngioDynamics. MarketBeat recorded 13 mentions for FocalTherics and 3 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.86 beat FocalTherics' score of 0.54 indicating that AngioDynamics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AngioDynamics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
FocalTherics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 62.7% of FocalTherics shares are owned by institutional investors. 6.0% of AngioDynamics shares are owned by insiders. Comparatively, 10.1% of FocalTherics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AngioDynamics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

AngioDynamics presently has a consensus price target of $19.00, suggesting a potential upside of 60.07%. FocalTherics has a consensus price target of $9.67, suggesting a potential upside of 198.35%. Given FocalTherics' higher possible upside, analysts plainly believe FocalTherics is more favorable than AngioDynamics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AngioDynamics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
FocalTherics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

AngioDynamics has a net margin of -10.12% compared to FocalTherics' net margin of -59.77%. AngioDynamics' return on equity of -4.49% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
AngioDynamics-10.12% -4.49% -2.96%
FocalTherics -59.77%-223.32%-41.32%

Summary

AngioDynamics beats FocalTherics on 10 of the 16 factors compared between the two stocks.

How does FocalTherics compare to Shoulder Innovations?

FocalTherics (NASDAQ:FOCL) and Shoulder Innovations (NYSE:SI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Comparatively, 29.0% of Shoulder Innovations shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, FocalTherics had 10 more articles in the media than Shoulder Innovations. MarketBeat recorded 13 mentions for FocalTherics and 3 mentions for Shoulder Innovations. FocalTherics' average media sentiment score of 0.54 beat Shoulder Innovations' score of 0.28 indicating that FocalTherics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
FocalTherics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Shoulder Innovations
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

FocalTherics currently has a consensus target price of $9.67, indicating a potential upside of 198.35%. Shoulder Innovations has a consensus target price of $25.75, indicating a potential upside of 24.58%. Given FocalTherics' higher probable upside, analysts plainly believe FocalTherics is more favorable than Shoulder Innovations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FocalTherics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Shoulder Innovations
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

FocalTherics has higher revenue and earnings than Shoulder Innovations. Shoulder Innovations is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FocalTherics$70.53M1.72-$29.25M-$0.98N/A
Shoulder Innovations$47.32M9.14-$40.36M-$1.62N/A

FocalTherics has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market. Comparatively, Shoulder Innovations has a beta of -1.51, meaning that its stock price is 251% less volatile than the broader market.

Shoulder Innovations has a net margin of -51.72% compared to FocalTherics' net margin of -59.77%. Shoulder Innovations' return on equity of -25.37% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
FocalTherics-59.77% -223.32% -41.32%
Shoulder Innovations -51.72%-25.37%-20.87%

Summary

FocalTherics beats Shoulder Innovations on 10 of the 17 factors compared between the two stocks.

How does FocalTherics compare to NeuroPace?

FocalTherics (NASDAQ:FOCL) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, NeuroPace had 10 more articles in the media than FocalTherics. MarketBeat recorded 23 mentions for NeuroPace and 13 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.54 beat NeuroPace's score of -0.12 indicating that FocalTherics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
FocalTherics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeuroPace
1 Very Positive mention(s)
6 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

FocalTherics has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

NeuroPace has a net margin of -20.00% compared to FocalTherics' net margin of -59.77%. NeuroPace's return on equity of -117.31% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
FocalTherics-59.77% -223.32% -41.32%
NeuroPace -20.00%-117.31%-16.83%

NeuroPace has higher revenue and earnings than FocalTherics. NeuroPace is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FocalTherics$70.53M1.72-$29.25M-$0.98N/A
NeuroPace$99.99M2.59-$21.47M-$0.57N/A

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Comparatively, 19.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

FocalTherics currently has a consensus target price of $9.67, indicating a potential upside of 198.35%. NeuroPace has a consensus target price of $15.50, indicating a potential upside of 105.03%. Given FocalTherics' stronger consensus rating and higher possible upside, equities research analysts clearly believe FocalTherics is more favorable than NeuroPace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FocalTherics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
NeuroPace
1 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

NeuroPace beats FocalTherics on 12 of the 17 factors compared between the two stocks.

How does FocalTherics compare to Brainsway?

Brainsway (NASDAQ:BWAY) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, FocalTherics had 1 more articles in the media than Brainsway. MarketBeat recorded 13 mentions for FocalTherics and 12 mentions for Brainsway. FocalTherics' average media sentiment score of 0.54 beat Brainsway's score of -0.05 indicating that FocalTherics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Brainsway
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
FocalTherics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Brainsway has higher earnings, but lower revenue than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainsway$52.22M7.79$7.57M$0.5020.22
FocalTherics$70.53M1.72-$29.25M-$0.98N/A

Brainsway currently has a consensus target price of $18.20, suggesting a potential upside of 80.02%. FocalTherics has a consensus target price of $9.67, suggesting a potential upside of 198.35%. Given FocalTherics' higher possible upside, analysts clearly believe FocalTherics is more favorable than Brainsway.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainsway
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
FocalTherics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

30.1% of Brainsway shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 10.1% of FocalTherics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Brainsway has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

Brainsway has a net margin of 15.54% compared to FocalTherics' net margin of -59.77%. Brainsway's return on equity of 13.09% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
Brainsway15.54% 13.09% 8.50%
FocalTherics -59.77%-223.32%-41.32%

Summary

Brainsway beats FocalTherics on 11 of the 17 factors compared between the two stocks.

How does FocalTherics compare to Senseonics?

FocalTherics (NASDAQ:FOCL) and Senseonics (NASDAQ:SENS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

FocalTherics presently has a consensus target price of $9.67, suggesting a potential upside of 198.35%. Senseonics has a consensus target price of $14.40, suggesting a potential upside of 36.11%. Given FocalTherics' stronger consensus rating and higher probable upside, equities research analysts clearly believe FocalTherics is more favorable than Senseonics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FocalTherics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Senseonics
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

FocalTherics has a net margin of -59.77% compared to Senseonics' net margin of -204.01%. Senseonics' return on equity of -186.11% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
FocalTherics-59.77% -223.32% -41.32%
Senseonics -204.01%-186.11%-86.21%

In the previous week, Senseonics had 32 more articles in the media than FocalTherics. MarketBeat recorded 45 mentions for Senseonics and 13 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.54 beat Senseonics' score of 0.35 indicating that FocalTherics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
FocalTherics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Senseonics
7 Very Positive mention(s)
8 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

FocalTherics has higher revenue and earnings than Senseonics. Senseonics is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FocalTherics$70.53M1.72-$29.25M-$0.98N/A
Senseonics$60.01M7.37-$69.11M-$2.30N/A

62.7% of FocalTherics shares are held by institutional investors. Comparatively, 12.4% of Senseonics shares are held by institutional investors. 10.1% of FocalTherics shares are held by insiders. Comparatively, 4.7% of Senseonics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

FocalTherics has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Senseonics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Summary

FocalTherics beats Senseonics on 12 of the 17 factors compared between the two stocks.

Get FocalTherics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FOCL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FOCL vs. The Competition

MetricFocalThericsHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$127.97M$5.95B$7.85B$12.17B
Dividend YieldN/A1.69%2.46%4.41%
P/E RatioN/A35.6832.9127.37
Price / Sales1.695.448.595.73
Price / CashN/A23.9521.9322.50
Price / Book3.304.374.403.70
Net Income-$29.25M$143.12M$3.52B$392.17M
7 Day Performance-9.94%-4.86%-5.34%-4.53%
1 Month Performance-22.49%-2.87%-3.61%-5.86%
1 Year PerformanceN/A-0.76%0.01%-7.78%

FocalTherics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FOCL
FocalTherics
2.5611 of 5 stars
$3.17
-2.2%
$9.67
+204.9%
N/A$127.97M$70.53MN/A230
ANGO
AngioDynamics
3.0207 of 5 stars
$12.07
-0.4%
$19.00
+57.4%
-2.0%$507.54M$320.17MN/A632
SI
Shoulder Innovations
2.4455 of 5 stars
$21.89
+2.0%
$25.75
+17.6%
+40.5%$455.73M$47.32MN/A75
NPCE
NeuroPace
3.322 of 5 stars
$12.69
-3.3%
$20.50
+61.5%
-41.6%$435.52M$99.99MN/A220
BWAY
Brainsway
4.62 of 5 stars
$10.67
-8.3%
$18.20
+70.6%
+28.3%$429.47M$52.22M24.25129

Related Companies and Tools


This page (NASDAQ:FOCL) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners